Agenparl
Image default
Home » HUMAN MEDICINES EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR): ORPHACOL, CHOLIC ACID, DIGESTIVE SYSTEM DISEASES,METABOLISM, INBORN ERRORS, DATE OF AUTHORISATION: 12/09/2013, DATE OF REFUSAL: 25/05/2012, REVISION: 9, STATUS: AUTHORISED

HUMAN MEDICINES EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR): ORPHACOL, CHOLIC ACID, DIGESTIVE SYSTEM DISEASES,METABOLISM, INBORN ERRORS, DATE OF AUTHORISATION: 12/09/2013, DATE OF REFUSAL: 25/05/2012, REVISION: 9, STATUS: AUTHORISED

(AGENPARL) – LONDON (UNITED KINGDOM), mar 11 agosto 2020

Orphacol is a medicine containing cholic acid, a substance found in the bile, which is used to digest fats.

It is used to treat adults and children from one month of age who have a genetic abnormality that makes them unable to produce bile. Orphacol is used in patients who do not have enough of two specific liver enzymes (3β-hydroxy-Δ5-C27-steroid oxidoreductase or Δ4-3-oxosteroid-5β-reductase). This makes their liver unable to produce enough of the main components of bile, called primary bile acids, such as cholic acid. When these primary bile acids are lacking, the body produces abnormal bile acids instead which can damage the liver, potentially leading to life-threatening liver failure.

Because the number of patients with inborn errors in primary bile acid synthesis is low, the condition is considered ‘rare’, and Orphacol was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 18 December 2002.

Fonte/Source: https://www.ema.europa.eu/en/medicines/human/EPAR/orphacol

Post collegati

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More